These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 23609378)
1. Do atypical antipsychotics really enhance smoking reduction more than typical ones?: the effects of antipsychotics on smoking reduction in patients with schizophrenia. Wu BJ; Chen HK; Lee SM J Clin Psychopharmacol; 2013 Jun; 33(3):319-28. PubMed ID: 23609378 [TBL] [Abstract][Full Text] [Related]
2. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. George TP; Ziedonis DM; Feingold A; Pepper WT; Satterburg CA; Winkel J; Rounsaville BJ; Kosten TR Am J Psychiatry; 2000 Nov; 157(11):1835-42. PubMed ID: 11058482 [TBL] [Abstract][Full Text] [Related]
3. The effect of dopamine partial agonists on the nicotine dependency in patients with schizophrenia. Kim SH; Han DH; Joo SY; Min KJ Hum Psychopharmacol; 2010 Mar; 25(2):187-90. PubMed ID: 20033907 [TBL] [Abstract][Full Text] [Related]
4. Predictors of smoking reduction outcomes in a sample of 287 patients with schizophrenia spectrum disorders. Wu BJ; Lan TH Eur Arch Psychiatry Clin Neurosci; 2017 Feb; 267(1):63-72. PubMed ID: 26310877 [TBL] [Abstract][Full Text] [Related]
5. Atypical antipsychotics: mechanism of action. Seeman P Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706 [TBL] [Abstract][Full Text] [Related]
7. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. Evins AE; Cather C; Culhane MA; Birnbaum A; Horowitz J; Hsieh E; Freudenreich O; Henderson DC; Schoenfeld DA; Rigotti NA; Goff DC J Clin Psychopharmacol; 2007 Aug; 27(4):380-6. PubMed ID: 17632223 [TBL] [Abstract][Full Text] [Related]
8. Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics. Tyson PJ; Laws KR; Flowers KA; Tyson A; Mortimer AM Psychiatry Clin Neurosci; 2006 Aug; 60(4):473-9. PubMed ID: 16884450 [TBL] [Abstract][Full Text] [Related]
9. Readiness to quit as a predictor for outcomes of smoking-reduction programme with transdermal nicotine patch or bupropion in a sample of 308 patients with schizophrenia. Chou KJ; Chen HK; Hung CH; Chen TT; Chen CM; Wu BJ Eur Arch Psychiatry Clin Neurosci; 2015 Apr; 265(3):249-57. PubMed ID: 25005553 [TBL] [Abstract][Full Text] [Related]
10. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients. Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593 [TBL] [Abstract][Full Text] [Related]
12. The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. Chou KR; Chen R; Lee JF; Ku CH; Lu RB Int J Nurs Stud; 2004 Mar; 41(3):321-30. PubMed ID: 14967189 [TBL] [Abstract][Full Text] [Related]
13. Characteristics of COPD smokers and effectiveness and safety of smoking cessation medications. Jiménez Ruiz CA; Ramos Pinedo A; Cicero Guerrero A; Mayayo Ulibarri M; Cristobal Fernández M; Lopez Gonzalez G Nicotine Tob Res; 2012 Sep; 14(9):1035-9. PubMed ID: 22345320 [TBL] [Abstract][Full Text] [Related]
14. Smoking and schizophrenia. Sagud M; Mihaljević-Peles A; Mück-Seler D; Pivac N; Vuksan-Cusa B; Brataljenović T; Jakovljević M Psychiatr Danub; 2009 Sep; 21(3):371-5. PubMed ID: 19794359 [TBL] [Abstract][Full Text] [Related]
15. Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Johnston JA; Fiedler-Kelly J; Glover ED; Sachs DP; Grasela TH; DeVeaugh-Geiss J Nicotine Tob Res; 2001 May; 3(2):131-40. PubMed ID: 11403727 [TBL] [Abstract][Full Text] [Related]
17. A review of the effects of nicotine on schizophrenia and antipsychotic medications. Lyon ER Psychiatr Serv; 1999 Oct; 50(10):1346-50. PubMed ID: 10506305 [TBL] [Abstract][Full Text] [Related]
18. [Brain in the core of metabolic regulations: disorders in schizophrenic patients treated with atypical antipsychotics]. Hanssens L; Scheen AJ; van Winkel R; Van Eyck D; Reginster JY; De Hert M Rev Med Liege; 2008; 63(5-6):417-23. PubMed ID: 18669214 [TBL] [Abstract][Full Text] [Related]
19. Smoking and schizophrenia: is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use? Barnes M; Lawford BR; Burton SC; Heslop KR; Noble EP; Hausdorf K; Young RM Aust N Z J Psychiatry; 2006; 40(6-7):575-80. PubMed ID: 16756583 [TBL] [Abstract][Full Text] [Related]
20. Potent Dopamine D2 Antagonists Block the Reward-Enhancing Effects of Nicotine in Smokers With Schizophrenia. Whitton AE; Green AI; Pizzagalli DA; Roth RM; Williams JM; Brunette MF Schizophr Bull; 2019 Oct; 45(6):1300-1308. PubMed ID: 30690638 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]